- 1.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015; 63: 971–1004. [PubMed][CrossRef]
- 2.
Mack CL, Adams D, Assis DN et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases. Hepatology 2020; 72: 671–722. [PubMed][CrossRef]
- 3.
Boberg KM, Aadland E, Jahnsen J et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33: 99–103. [PubMed][CrossRef]
- 4.
Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014; 60: 612–7. [PubMed][CrossRef]
- 5.
Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159–85. [PubMed][CrossRef]
- 6.
Werner M, Prytz H, Ohlsson B et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008; 43: 1232–40. [PubMed][CrossRef]
- 7.
van Gerven NM, Verwer BJ, Witte BI et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol 2014; 49: 1245–54. [PubMed][CrossRef]
- 8.
Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929–38. [PubMed][CrossRef]
- 9.
Hennes EM, Zeniya M, Czaja AJ et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169–76. [PubMed][CrossRef]
- 10.
Lohse AW. Recognizing autoimmune hepatitis: scores help, but no more. J Hepatol 2011; 54: 193–4. [PubMed][CrossRef]
- 11.
Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009; 29: 816–23. [PubMed][CrossRef]
- 12.
Lohse AW, Sebode M, Jørgensen MH et al. Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. J Hepatol 2020; 73: 1496–506. [PubMed][CrossRef]
- 13.
Soloway RD, Summerskill WH, Baggenstoss AH et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820–33. [PubMed][CrossRef]
- 14.
Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735–7. [PubMed][CrossRef]
- 15.
Manns MP, Woynarowski M, Kreisel W et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198–206. [PubMed][CrossRef]
- 16.
Santiago P, Schwartz I, Tamariz L et al. Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther 2019; 49: 830–9. [PubMed][CrossRef]
- 17.
Roberts SK, Lim R, Strasser S et al. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy. Clin Gastroenterol Hepatol 2018; 16: 268–77. [PubMed][CrossRef]
- 18.
Sharzehi K, Huang MA, Schreibman IR et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010; 24: 588–92. [PubMed][CrossRef]
- 19.
Zachou K, Gatselis N, Papadamou G et al. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol 2011; 55: 636–46. [PubMed][CrossRef]
- 20.
Efe C, Hagström H, Ytting H et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 2017; 15: 1950–1956.e1. [PubMed][CrossRef]
- 21.
Pape S, Nevens F, Verslype C et al. Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience. Eur J Gastroenterol Hepatol 2020; 32: 727–32. [PubMed][CrossRef]
- 22.
Muratori P, Fabbri A, Lalanne C et al. Autoimmune liver disease and concomitant extrahepatic autoimmune disease. Eur J Gastroenterol Hepatol 2015; 27: 1175–9. [PubMed][CrossRef]
- 23.
Bittencourt PL, Farias AQ, Porta G et al. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J Clin Gastroenterol 2008; 42: 300–5. [PubMed][CrossRef]
- 24.
Haraldsplass Diakonale Sykehus. Nasjonalt nettverk for autoimmune leversykdommer. https://www.haraldsplass.no/helsefaglig/forskning-og-utvikling/nasjonalt-nettverk-for-autoimmune-leversykdommer Lest 28.4.2021.
- 25.
Braga A, Vasconcelos C, Braga J. Autoimmune hepatitis and pregnancy. Best Pract Res Clin Obstet Gynaecol 2020; 68: 23–31. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.